Thus, we investigated whether inhibition of TOP1 degradation using NEDD8-activating enzyme inhibitor MLN4924 could result in better anti-tumor effects of 10-HCPT in HNSCC treatment. This evidence concerns the gene TOP1 and neoplasm.